1. Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease
- Author
-
Keiji Hirai, Shohei Kaneko, Saori Minato, Katsunori Yanai, Momoko Hirata, Taisuke Kitano, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, and Yoshiyuki Morishita
- Subjects
roxadustat ,anemia ,cholesterol ,triglyceride ,chronic kidney disease ,erythropoiesis-stimulating agent ,Medicine (General) ,R5-920 - Abstract
BackgroundWe determined the effects of roxadustat on the values of anemia, iron metabolism, renal function, proteinuria, and lipid metabolism and identified the associated factors of the change in hemoglobin levels after roxadustat administration in non-dialysis chronic kidney disease (CKD) patients who were receiving an erythropoietin-stimulating agent (ESA).MethodsWe conducted retrospective analysis of the changes in hemoglobin, serum ferritin, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride levels; transferrin saturation; the estimated glomerular filtration rate; and the urinary protein/creatinine ratio over 24 weeks after the change from an ESA to roxadustat in 50 patients with non-dialysis CKD and anemia (roxadustat group). Seventy-two patients with non-dialysis CKD and anemia who proceeded ESA therapy were used as the control (ESA) group.ResultsWe observed no significant between-group differences in clinical parameters at baseline except for the significantly lower hemoglobin concentration and lower proportion of diabetes mellitus in the roxadustat group. The hemoglobin concentration was significantly higher in the roxadustat group after 24 weeks (11.3 ± 1.2 versus 10.3 ± 1.0 g/dL; value of p
- Published
- 2023
- Full Text
- View/download PDF